Get the Stockscreener App
30.38
0.30%
0.09
After Hours:
30.32
-0.06
-0.20%
Viking Therapeutics Inc stock is traded at $30.38, with a volume of 3.36M.
It is up +0.30% in the last 24 hours and up +5.89% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$30.29
Open:
$30.49
24h Volume:
3.36M
Relative Volume:
1.53
Market Cap:
$3.53B
Revenue:
-
Net Income/Loss:
$-472.34M
P/E Ratio:
-7.3277
EPS:
-4.1459
Net Cash Flow:
$-340.33M
1W Performance:
+6.19%
1M Performance:
+5.89%
6M Performance:
-10.52%
1Y Performance:
+15.60%
1-Day Range:
$30.16
$31.60
1-Week Range:
$28.49
$31.60
52-Week Range:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
30.38 | 3.52B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Liquidity Mapping Around (VKTX) Price Events - Stock Traders Daily
Viking Therapeutics Inc (VKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viking Therapeutics, Inc. (VKTX) gains as market dips: What you should know - MSN
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - Yahoo Finance
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity - Insider Monkey
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - Sahm
VKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm
symbol__ Stock Quote Price and Forecast - CNN
VKTX News | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Is Viking Therapeutics Stock Going to $100? - AOL.com
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - GuruFocus
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance
VKTX Stock Price, Quote & Chart - ChartMill
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
8-K: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatemoomoo - Moomoo
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma
Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus
Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com
Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz
Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com
Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView
Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN
VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com
Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500
Viking Therapeutics, Inc. (VKTX) falls more steeply than broader market: What investors need to know - MSN
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven (VKTX) - Seeking Alpha
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Why (VKTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Current ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Asset turnover of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VT - TradingView
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
Viking Therapeutics, Inc. Revenue Breakdown – XETR:1VT - TradingView
Viking Therapeutics, Inc. Cash Flow – XETR:1VT - TradingView
Viking Therapeutics, Inc. Balance Sheet – XETR:1VT - TradingView
Viking Therapeutics, Inc. Statistics – XETR:1VT - TradingView
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):